Effects of naproxen and nabumetone on serum cholesterol levels in patients with osteoarthritis

Young, David M.

doi:10.1016/0149-2918(95)80021-2

Cited by 6 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was determined that diclofenac treatment increased ( P < 0.011) the concentration of plasma HDL, while it decreased ( P < 0.002) the concentration of LDL (Table 2). Similar results were reported following aspirin, naproxen, and ibuprophene treatments [25–27]. Paradoxically, diclofenac caused decrement ( P < 0.006) in WBC, whereas it increased ( P < 0.019) RBC in this study (Table 3).…”

Section: Discussionsupporting

confidence: 89%

Cardiac Safety of Diclofenac at a Single Dose in Ram

Dik

Çorum

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs are frequently prescribed drug group in human and veterinary medicine. However, diclofenac, a traditional nonsteroidal anti-inflammatory drug, related to cardiotoxicity is reported, and blood cardiac damage markers may increase within the first hours after damage. The aim of the current research was to determine the effect of diclofenac on the blood cardiac damage markers. Single dose of diclofenac (2.5 mg/kg, IM) was injected to 6 rams. Blood samples were collected in before (0 hour, control) and 6 hours after injection. Specific (troponin I, and creatine kinase-MB) and nonspecific (lactate dehydrogenase, aspartate aminotransferase) blood cardiac damage marker concentrations, routine biochemical (hepatic damage, renal damage, lipid metabolism, glucose, and phosphorus) parameters, and hemogram values were measured. Diclofenac increased (P < 0.05) specific (troponin I) and nonspecific cardiac (lactate dehydrogenase, aspartate aminotransferase), hepatic (aspartate aminotransferase, alkaline phosphatase, and alanine aminotransferase), and muscular (creatine kinase) damage markers and high density lipoprotein level, while it decreased (P < 0.05) low density lipoprotein level. Moreover, diclofenac decreased (P < 0.05) white blood cell counts and increased (P < 0.05) red blood cell counts. In conclusion, it may be stated that diclofenac shows slight cardiotoxicity, whereas it may show potent hepatic and muscular damage effects at an intramuscularly single dose in sheep. Thereby, repeated injections of diclofenac may be more harmful in sheep.

show abstract

Section: Discussionsupporting

confidence: 89%

Cardiac Safety of Diclofenac at a Single Dose in Ram

Dik

Çorum

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…However, these effects apparently did not translate into increased HDL generation, as similar plasma HDL-C levels were noted in a small prospective study in aspirinand placebo-treated groups (Eritsland et al 1989). In one study, the administration of ibuprofen was found to slightly elevate HDL-C levels both in smokers and nonsmokers, whereas in another study treatment with naproxen failed to show any effect (Zapolska-Downar et al 2000;Young et al 1995). The influence of selective cyclooxygenase-2 inhibitors such as celecoxib or rofecoxib on HDL-C plasma levels has not been reported to date.…”

mentioning

confidence: 86%

Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions

Montecucco

Favari

Norata

et al. 2014

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions.

show abstract

“…On the other hand; the lipid levels determined in these studies were well above the upper ranges found in our study. Some drugs could potentially affect lipid and lipoprotein levels (20)(21)(22), and because of this many patients in our study who had been previously diagnosed and were using these drug types were excluded. In our study 15 (12.3 %) FMS patients interestingly their TC levels were well above 200 mg/dl.…”

Section: Resultsmentioning

confidence: 99%

Demographic Analysis and Lipid profile in Fibromyalgia Syndrome

Farid,

Turki,

Al-Osami

2011

JFacMedBagdad

View full text Add to dashboard Cite

Background: Fibromyalgia syndrome (FMS) is a very common cause of multiple regional musculoskeletal (MSK) pain and disability; it is characterized by chronic widespread for at leastthree months and tender points identified by the American Collage of Rheumatology (ACR).The cause of FMS is currently unknown. However, several hypotheses have been developed including genetic predisposition. This study aims to evaluate the contribution of serum lipid profile to the pathophysiology of FMS.Patients & Methods: The study has included 160 patients with FMS with age range (18-72) years and 60 control individuals who were age and sex matching with FMS patients: 29 patients with chronic musculoskeletal complaints but without FMS and 31 healthy controls. Colorimetric method was used to determine serum lipid profile. Results were evaluated using descriptive and inferential statistics; data were expressed as (mean ± SEM). P value of <0.05 was accepted as significant.Results: There were no significant differences among the three subject groups in serum lipid profile.Conclusion: Lipid profile has no role in FMS patients as a cause or result of this syndrome.

show abstract

Effects of naproxen and nabumetone on serum cholesterol levels in patients with osteoarthritis

Cited by 6 publications

References 15 publications

Cardiac Safety of Diclofenac at a Single Dose in Ram

Cardiac Safety of Diclofenac at a Single Dose in Ram

Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions

Demographic Analysis and Lipid profile in Fibromyalgia Syndrome

Contact Info

Product

Resources

About